Treatment Of JIA-associated Uveitis Research Articles

The use of biologics in the treatment of JIA-associated uveitis in a pediatric cohort: a single-center retrospective analysis

Juvenile idiopathic artiritis (JIA) is the most common systemic disorder associated with pediatric uveitis. This study analyzes the outcome of biologic therapy in children with JIA-associated uveitis (JIA-U) regarding the control of ocular inflammation, steroid dependence and visual outcome.

Recommendations for the Management of Uveitis Associated With Juvenile Idiopathic Arthritis: The Czech and Slovak adaptation of SHARE Initiative.

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is its most important extra-articular manifestation. Evidence-based recommendations are available only to alimited extent and therefore JIA associated uveitis management is mostly based on physicians experience. Consequently, treatment practices differ widely, both nationally and internationally. Therefore, an effort to optimize and publish recommendations for the care of children and young adults with rheumatic diseases was launched in 2012 as part of the international project SHARE (Single Hub and Access Point for Pediatric Rheumatology in Europe) to facilitate clinical practice for paediatricians and (paediatric) rheumatologists. The aim of this work was to translate published international SHARE recommendations for the diagnosis and treatment of JIA associated uveitis and to adapt them for use in the Czech and Slovak Republics. International recommendations were developed according to the standard methodology of the European League against Rheumatism (EULAR) by agroup of nine experienced paediatric rheumatologists and three experts in ophthalmology. It was based on asystematic literature review and evaluated in the form of an online survey and subsequently discussed using anominal group technique. Recommendations were accepted if > 80% agreement was reached (including all three ophthalmologists). Atotal of 22 SHARE recommendations were accepted: 3 on diagnosis, 5 on disease activity assessment, 12 on treatment and 2 on future recommendations. Translation of the original text was updated and modified with data specific to the czech and slovak health care systems and supplemented with aproposal for aprotocol of ophthalmological dispensarization of paediatric JIA patients and atreatment algorithm for JIA associated uveitis. Conclusion: The aim of the SHARE initiative is to improve and standardize care for paediatric patients with rheumatic diseases across Europe. Therefore, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated based on the evidence and agreement of leading European experts in this field.

Особливості перебігу та лікування увеїтів, асоційованих з ювенільним ідіопатичним артритом у дітей

Особливості перебігу та лікування увеїтів, асоційованих з ювенільним ідіопатичним артритом у дітей

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative

BackgroundIn 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for...

Juvenile idiopathic arthritis-associated uveitis

To describe recent evidence from the literature pertaining to juvenile idiopathic arthritis (JIA)-associated uveitis. Uveitis is most common in extended oligoarticular JIA. A significant number of patients already have ocular complications at time of diagnosis of uveitis. Risk factors for complications include either abnormally high or low intraocular pressure, posterior synechiae, male sex, temporal proximity to diagnosis of arthritis and topical corticosteroid use. Use of immunosuppressive agents significantly reduces ocular complications. Aggressive perioperative control of intraocular inflammation is necessary for successful cataract surgery with lens implantation. Controlled clinical trials are under way to assess the efficacy of biologic agents in JIA-associated uveitis. Long-term safety, however, is still unknown. JIA-associated uveitis carries significant ocular morbidity that lasts well into adulthood. Treatment with immunosuppressive agents can reduce the risk of ocular complications. Biologic agents hold promise in the treatment of JIA-associated uveitis, but require long-term data to assess their safety.